SK3302004A3 - Tuhé liekové formy s riadeným uvoľňovaním účinnej látky - nový systém dodávania liečiva so zníženým rizikom nekontrolovaného uvoľňovania účinnej látky - Google Patents
Tuhé liekové formy s riadeným uvoľňovaním účinnej látky - nový systém dodávania liečiva so zníženým rizikom nekontrolovaného uvoľňovania účinnej látky Download PDFInfo
- Publication number
- SK3302004A3 SK3302004A3 SK330-2004A SK3302004A SK3302004A3 SK 3302004 A3 SK3302004 A3 SK 3302004A3 SK 3302004 A SK3302004 A SK 3302004A SK 3302004 A3 SK3302004 A3 SK 3302004A3
- Authority
- SK
- Slovakia
- Prior art keywords
- pharmaceutical composition
- water
- composition according
- weight
- insoluble
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000013270 controlled release Methods 0.000 title claims abstract description 44
- 238000009472 formulation Methods 0.000 title claims abstract description 11
- 239000007787 solid Substances 0.000 title claims description 16
- 238000012377 drug delivery Methods 0.000 title description 7
- 239000000463 material Substances 0.000 claims abstract description 48
- 239000013543 active substance Substances 0.000 claims abstract description 44
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 24
- 239000003826 tablet Substances 0.000 claims description 58
- 239000008187 granular material Substances 0.000 claims description 56
- 239000002552 dosage form Substances 0.000 claims description 48
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 31
- 229920003152 Eudragit® RS polymer Polymers 0.000 claims description 26
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims description 26
- 229960000620 ranitidine Drugs 0.000 claims description 22
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 22
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 21
- 229960005461 torasemide Drugs 0.000 claims description 21
- 239000000454 talc Substances 0.000 claims description 20
- 229910052623 talc Inorganic materials 0.000 claims description 20
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 18
- 229960001193 diclofenac sodium Drugs 0.000 claims description 16
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims description 15
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 15
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 15
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000008101 lactose Substances 0.000 claims description 14
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 11
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 10
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 10
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 7
- 238000009501 film coating Methods 0.000 claims description 7
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 6
- 239000007909 solid dosage form Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000002861 polymer material Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 12
- 230000002459 sustained effect Effects 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 238000013268 sustained release Methods 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 description 37
- 239000011777 magnesium Substances 0.000 description 37
- 239000003814 drug Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 24
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 239000008186 active pharmaceutical agent Substances 0.000 description 9
- 238000007922 dissolution test Methods 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000007900 aqueous suspension Substances 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 229940088679 drug related substance Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000006835 compression Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical class C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 229920003164 Eudragit® NE 40 D Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- -1 adhesion Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000002484 anti-cholesterolemic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960001495 pravastatin sodium Drugs 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003169 respiratory stimulant agent Substances 0.000 description 1
- 229940066293 respiratory stimulants Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20020124A HRP20020124A2 (en) | 2002-02-11 | 2002-02-11 | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
| PCT/HR2002/000018 WO2003074033A1 (fr) | 2002-02-11 | 2002-03-27 | Formulation solide a liberation prolongee/controlee en tant que nouveau systeme d'administration de medicaments a risque reduit de liberation massive |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3302004A3 true SK3302004A3 (sk) | 2005-04-01 |
Family
ID=27772919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK330-2004A SK3302004A3 (sk) | 2002-02-11 | 2002-03-27 | Tuhé liekové formy s riadeným uvoľňovaním účinnej látky - nový systém dodávania liečiva so zníženým rizikom nekontrolovaného uvoľňovania účinnej látky |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20050118266A1 (fr) |
| EP (1) | EP1474112A1 (fr) |
| JP (1) | JP2006507216A (fr) |
| AU (1) | AU2004205184A1 (fr) |
| BG (1) | BG108870A (fr) |
| CA (1) | CA2476050A1 (fr) |
| CZ (1) | CZ2004931A3 (fr) |
| EE (1) | EE200400110A (fr) |
| HR (1) | HRP20020124A2 (fr) |
| HU (1) | HUP0500097A3 (fr) |
| IS (1) | IS7386A (fr) |
| NO (1) | NO20043818L (fr) |
| PL (1) | PL371787A1 (fr) |
| RS (1) | RS70704A (fr) |
| RU (1) | RU2004127237A (fr) |
| SK (1) | SK3302004A3 (fr) |
| WO (1) | WO2003074033A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2244324B1 (es) | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| US8481565B2 (en) * | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
| US20060246003A1 (en) * | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| DE102006051020A1 (de) * | 2006-10-26 | 2008-04-30 | Evonik Röhm Gmbh | Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung |
| US9015057B2 (en) | 2007-09-25 | 2015-04-21 | Neosync, Inc. | Systems and methods for controlling and billing neuro-EEG synchronization therapy |
| US8926490B2 (en) * | 2008-09-24 | 2015-01-06 | Neosync, Inc. | Systems and methods for depression treatment using neuro-EEG synchronization therapy |
| WO2011017466A1 (fr) | 2009-08-06 | 2011-02-10 | Neosync, Inc. | Systèmes et procédés pour la modulation de lactivité électrique dun cerveau en utilisant un traitement de synchronisation neuro-eeg |
| EP2480212B1 (fr) * | 2009-09-25 | 2016-07-06 | Novartis Consumer Health S.A. | Composition pharmaceutique orale contenant du diclofenac |
| EP4094689A1 (fr) | 2009-11-12 | 2022-11-30 | Neosync, INC. | Systèmes et procédés pour une synchronisation neuro-électro-encéphalographique (eeg) |
| EP2540318B1 (fr) | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Préparation solide à libération prolongée pour utilisation orale |
| JP5714562B2 (ja) | 2010-02-22 | 2015-05-07 | 第一三共株式会社 | 経口用徐放性固形製剤 |
| EA029077B1 (ru) * | 2010-03-09 | 2018-02-28 | Алкермес Фарма Айэленд Лимитед | Устойчивая к спирту фармацевтическая лекарственная форма |
| ES2706994T3 (es) | 2012-09-03 | 2019-04-02 | Daiichi Sankyo Co Ltd | Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona |
| US20150238451A1 (en) * | 2012-10-19 | 2015-08-27 | Wockhardt Limited | Pharmaceutical compositions of diclofenac or salts thereof |
| US10588576B2 (en) | 2014-08-15 | 2020-03-17 | Neosync, Inc. | Methods and device for determining a valid intrinsic frequency |
| JP1602547S (fr) | 2017-01-17 | 2018-04-23 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN156886B (fr) * | 1981-08-22 | 1985-11-30 | Council Scient Ind Res | |
| NL8500724A (nl) * | 1985-03-13 | 1986-10-01 | Univ Groningen | Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| NZ231281A (en) * | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
| US4948581A (en) * | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
| JP2572673B2 (ja) * | 1990-07-25 | 1997-01-16 | エスエス製薬株式会社 | 徐放性錠剤 |
| ES2107685T3 (es) * | 1992-10-16 | 1997-12-01 | Glaxo Group Ltd | Composiciones de ranitidina que enmascaran su sabor. |
| US6183778B1 (en) * | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| DE19524753A1 (de) * | 1995-07-07 | 1997-01-23 | Lohmann Therapie Syst Lts | Schichttablette zur kontrollierten Freisetzung von Wirkstoffen |
| ATE220543T1 (de) * | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
| EE03902B1 (et) * | 1996-05-20 | 2002-12-16 | Janssen Pharmaceutica N.V. | Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend |
| US6294199B1 (en) * | 1999-04-13 | 2001-09-25 | Beecham Pharmaceuticals (Pte) Limited | Method of treating a bacterial infection comprising administering amoxycillin |
-
2002
- 2002-02-11 HR HR20020124A patent/HRP20020124A2/hr not_active Application Discontinuation
- 2002-03-27 JP JP2003572553A patent/JP2006507216A/ja active Pending
- 2002-03-27 RS YU70704A patent/RS70704A/sr unknown
- 2002-03-27 SK SK330-2004A patent/SK3302004A3/sk not_active Application Discontinuation
- 2002-03-27 CZ CZ2004931A patent/CZ2004931A3/cs unknown
- 2002-03-27 HU HU0500097A patent/HUP0500097A3/hu unknown
- 2002-03-27 EP EP02708556A patent/EP1474112A1/fr not_active Withdrawn
- 2002-03-27 PL PL02371787A patent/PL371787A1/xx unknown
- 2002-03-27 CA CA002476050A patent/CA2476050A1/fr not_active Abandoned
- 2002-03-27 WO PCT/HR2002/000018 patent/WO2003074033A1/fr active Application Filing
- 2002-03-27 US US10/504,014 patent/US20050118266A1/en not_active Abandoned
- 2002-03-27 RU RU2004127237/15A patent/RU2004127237A/ru not_active Application Discontinuation
- 2002-03-27 EE EEP200400110A patent/EE200400110A/xx unknown
-
2004
- 2004-08-05 IS IS7386A patent/IS7386A/is unknown
- 2004-08-23 AU AU2004205184A patent/AU2004205184A1/en not_active Abandoned
- 2004-09-10 NO NO20043818A patent/NO20043818L/no not_active Application Discontinuation
- 2004-09-10 BG BG108870A patent/BG108870A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006507216A (ja) | 2006-03-02 |
| HRP20020124A2 (en) | 2003-10-31 |
| CZ2004931A3 (cs) | 2005-03-16 |
| CA2476050A1 (fr) | 2003-09-12 |
| EP1474112A1 (fr) | 2004-11-10 |
| EE200400110A (et) | 2004-10-15 |
| RU2004127237A (ru) | 2005-04-20 |
| IS7386A (is) | 2004-08-05 |
| HUP0500097A3 (en) | 2008-04-28 |
| BG108870A (en) | 2005-12-30 |
| HUP0500097A2 (hu) | 2005-07-28 |
| RS70704A (en) | 2006-10-27 |
| US20050118266A1 (en) | 2005-06-02 |
| WO2003074033A1 (fr) | 2003-09-12 |
| NO20043818L (no) | 2004-09-30 |
| WO2003074033A8 (fr) | 2004-07-08 |
| PL371787A1 (en) | 2005-06-27 |
| AU2004205184A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101406767B1 (ko) | 프라미펙솔 또는 약제학적으로 허용되는 이의 염을함유하는 연장 방출성 정제 제형, 이의 제조방법 및 이의용도 | |
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| US20090124702A1 (en) | Pharmaceutical Compositions of Metformin | |
| CA2483199C (fr) | Comprime d'imatinib a forte charge medicamenteuse | |
| SK3302004A3 (sk) | Tuhé liekové formy s riadeným uvoľňovaním účinnej látky - nový systém dodávania liečiva so zníženým rizikom nekontrolovaného uvoľňovania účinnej látky | |
| IL161491A (en) | Tamsulosin tablets | |
| US20110195120A2 (en) | Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride | |
| JP2014196334A (ja) | クエチアピンを含む徐放性医薬組成物 | |
| JPH03500288A (ja) | 徐放性ニフェジピン製剤 | |
| KR20010031952A (ko) | 카르베디롤을 위한 신규 경구 투여형 | |
| HRP940198A2 (en) | Retarded-action microtablet made of beta-phenylpropiophenone derivatives | |
| US20150359795A1 (en) | High drug load pharmaceutical compositions with controllable release rate and production methods thereof | |
| CA2781826A1 (fr) | Compositions pharmaceutiques a liberation controlee de galantamine | |
| WO2022153330A1 (fr) | Compositions pharmaceutiques comprenant de l'acalabrutinib | |
| EP2010158B1 (fr) | Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée | |
| EP2480234B1 (fr) | Composition de ranolazine à libération prolongée | |
| US11260055B2 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
| KR20200077911A (ko) | 잘토프로펜 함유 서방성 의약 조성물 | |
| PL204079B1 (pl) | Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania | |
| SK286119B6 (sk) | Lieková forma obsahujúca zaleplon | |
| WO2015150948A1 (fr) | Compositions pharmaceutiques orales solides à libération modifiée de cyclobenzaprine ou d'un sel de cette dernière | |
| WO2016042566A1 (fr) | Formulation de trimétazidine à libération prolongée | |
| WO2013111147A1 (fr) | Compositions à libération prolongée de névirapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |